Intelligent Bio Solutions (INBS, Financial) has reported notable advancements in its global operations, highlighted by the addition of new accounts and expansion into various testing areas and sectors. The company's recent achievements include an increase in its active accounts, now exceeding 450, and the inclusion of 35 new accounts in the third fiscal quarter alone.
INBS' innovative Intelligent Fingerprinting Drug Screening System, known for its ability to detect recent drug use quickly through fingerprint sweat analysis, is gaining popularity for its rapid results, portability, and user-friendly design. These developments are in line with INBS' strategy to localize and expand internationally, with a focus on high-demand markets.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Intelligent Bio Solutions Inc (INBS, Financial) is $12.00 with a high estimate of $12.00 and a low estimate of $12.00. The average target implies an upside of 833.85% from the current price of $1.29. More detailed estimate data can be found on the Intelligent Bio Solutions Inc (INBS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Intelligent Bio Solutions Inc's (INBS, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
